Key Insights on Gross Profit: BioMarin Pharmaceutical Inc. vs Alkermes plc

A Decade of Growth: BioMarin vs. Alkermes

In the competitive landscape of biopharmaceuticals, BioMarin Pharmaceutical Inc. and Alkermes plc have shown remarkable growth in gross profit over the past decade. Since 2014, BioMarin has consistently outperformed Alkermes, with its gross profit increasing by nearly 200% by 2023. In contrast, Alkermes has seen a more dramatic rise, with a staggering 726% increase in the same period.

Key Insights

• BioMarin's Steady Climb: Starting at approximately $621 million in 2014, BioMarin's gross profit reached around $1.84 billion by 2023, reflecting a robust growth trajectory.
• Alkermes' Rapid Surge: Alkermes began with a modest $171 million in 2014, but by 2023, it had soared to $1.41 billion, showcasing its aggressive market expansion.

These trends highlight the dynamic nature of the biopharmaceutical industry, where strategic innovation and market adaptation are key to sustained success.